S1p receptor modulators for treating multiple sclerosis
OwnerPeter C. Hiestand, Christian Schnellinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula X for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
Claims12
1-3. (canceled)
A method according to claim 7, wherein the medicament is co-administered, e.g. concomitantly or in sequence, with a VEGF-receptor antagonist.
A pharmaceutical composition for use in the method according to claim 7, comprising an S1P receptor modulator together with one or more pharmaceutically acceptable diluents or carriers therefor.
A pharmaceutical combination, e.g. a kit, comprising a) a first agent which is a S1P receptor modulator, in free form or in pharmaceutically acceptable salt form, and b) a VEGF-receptor antagonist.
A method for preventing, inhibiting or treating neo-angiogenesis associated with a demyelinating disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator.
A method according to claim 14, wherein the S1P receptor modulator or agonist is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl]ethyl-1,3-propane-diol, or 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, in free form or in a pharmaceutically acceptable salt form.
Dependencies are inferred from the claim text.